3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Breast Neoplasms
4
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Stomach Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Muscle Invasive Bladder Cancer (MIBC)
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
Cisplatin
141
Radiotherapy
115
Cetuximab
95
Docetaxel
69
Radiotherapy, Intensity-Modulated
55
Carboplatin
47
pembrolizumab
46
Surveys and Questionnaires
46
Paclitaxel
41
Fluorouracil
39
Radiation
29
Blood Specimen Collection
27
Drug Therapy
26
Erlotinib Hydrochloride
23
Nivolumab
21
Surgical Procedures, Operative
17
Standard of Care
16
Magnetic Resonance Spectroscopy
16
Radiosurgery
14
Pemetrexed
14
Gemcitabine
14
Everolimus
13
Celecoxib
13
durvalumab
12
Low-Level Light Therapy
12
Immunohistochemistry
12
Cyclophosphamide
12
Capecitabine
12
Amifostine
12
Chemoradiotherapy
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Head and Neck Neoplasms
×
zanidatamab
×
Clear all
NCT07192068
2025-12-19
AcSé HER2
UNICANCER
Phase 2
Recruiting
105 enrolled